INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third most common cancer in males and the second in females, with 746 and 614 thousand incidences in 2012 for both sexes, respectively, according to the GLOBOCAN statistics \[[@R1]\]. The overall mortality of this deadly cancer is 51% (694 thousand), indicating a very poor prognosis. In China, the total occurrence of CRC is 253 thousand in 2012, with a more serious mortality rate of 55% \[[@R1]\]. There is an urgent need to identify reliable markers for early diagnosis of CRC and evaluation of prognosis after curable resection.

Collagen type III alpha 1 (*COL3A1*) is one of the member of collagen family and mainly expressed in extensible connective tissues including skin and vessels. Mutations in the coding region or the intron region of *COL3A1* gene leads to an arterial disease termed as Ehlers-Danlos syndrome (EDS) and affects patient survival \[[@R2]-[@R4]\]. Different genetic variants of *COL3A1* affects the recurrence and prognosis of stroke \[[@R5]\]. The functional variants of *COL3A1* can cause other cardiovascular abnormalities such as intracranial aneurysm \[[@R6]\]. *COL3A1* also plays important roles in cortical development and lamination \[[@R7]\]. The upregulation of *COL3A1* in myofibroblasts contributes to pulmonary fibrosis \[[@R8]\]. *COL3A1* was found to be upregulated in several cancers \[[@R9]-[@R11]\], and was revealed to be a candidate diagnostic marker for mesothelioma \[[@R11]\].

The upregulation of *COL3A1* transcription was shown in colorectal cancers comparing with the normal counterparts by microarray gene expression analyses \[[@R12]-[@R14]\] and RNA-seq technique \[[@R15]\]. *COL3A1* transcription level was increased from adenoma to carcinoma \[[@R16]\], indicating an involvement of *COL3A1* in carcinogenesis. Interestingly, *COL3A1* was found to be substantially overexpressed in the liver invasion front of the colorectal liver metastases comparing with the tumor center and the normal tissue \[[@R17]\], suggesting a potential role of this gene in the metastasis process. Despite above findings, the functional roles and mechanism of *COL3A1* in tumorigenesis remains elucidative. The relationship of *COL3A1* overexpression with clinicopathological parameters and prognosis requires further explorations.

In current study, we analyzed the mRNA expression level of *COL3A1* in CRC tissue samples by interrogation of publically-available gene expression microarray datasets in Oncomine database. Furthermore, we analyzed the protein expression of COL3A1 protein in CRC using a tissue microarray (TMA) and immunohistochemistry (IHC). The relationship of *COL3A1* expression with the clinic parameters and prognosis outcome of CRC patients were addressed. The protein expression in the plasma of CRC patients was analyzed with enzyme-linked immunosorbent assay (ELISA). *In vitro* and *in vivo* assays were performed to address the function role of COL3A1.

RESULTS {#s2}
=======

*COL3A1* mRNA and protein were significantly upregulated in CRC {#s2_1}
---------------------------------------------------------------

We analyzed the differential expression of *COL3A1* mRNA in colon cancer tissues and the normal counterparts using six microarray gene expression datasets deposited in Oncomine database (DB). *COL3A1* was increased in the cancerous tissues comparing with the normal colonic tissues, as revealed in Gaedcke Colorectal, Hong Colorectal, Kaiser Colon and Skrzypczak Colorectal 2 datasets (Figure [1A-1D](#F1){ref-type="fig"}). Interestingly, in TCGA Colorectal dataset, *COL3A1* was found to be significantly higher in all types of colon cancers including cecum, colon, rectal, and rectosigmoid cancer (Figure [1E](#F1){ref-type="fig"}). The total cancer cases were 496 and the normal controls were 148 cases. The results indicated that the overexpression of *COL3A1* in colon cancers is common. *COL3A1* could be a molecular marker of colon cancer.

![Upregulation of *COL3A1* mRNA in CRC revealed by data-mining of the Oncomine gene expression database\
**A.** Gene expression of *COL3A1* is upregulated in rectal adenocarcinoma (AC) comparing with the normal rectum tissues revealed using Gaedcke Colorectal dataset from Oncomine DB (<https://www.oncomine.org/resource/login.html>) \[[@R22]\]. **B.** *COL3A1* gene expression in the normal and CRC tissues by Hong Colorectal dataset \[[@R28]\]. **C.** *COL3A1* expression changes between the normal tissues and cancer tissues of CRC by Kaiser Colon dataset \[[@R30]\]. **D.** *COL3A1* expression analysis in the micro-dissected normal, colorectal adenoma and CRC tissues by Skrzypczak Colorectal 2 dataset \[[@R29]\]. **E.** *COL3A1* expression changes between the normal tissues and different cancer tissues of CRC by TCGA dataset. The n indicates the total cases of different categories. The *p* values are shown above the transverse lines, which are calculated using two-tailed and unpaired Student\'s *t* test. The *p* value in the blanket is calculated using paired Student\'s *t* test.](oncotarget-07-8823-g001){#F1}

To address the protein expression of COL3A1 in colon cancers, we performed an IHC analysis of COL3A1 expression using a commercially available TMA containing 90 cases of colorectal adenocarcinoma, which 46 cases were completed and 44 were censored ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Negative and positive staining of COL3A1 in the epithelial cells were found in the normal colonic mucosa, while COL3A1 in lamina propria region was low in most cases (Figure [2A and 2B](#F2){ref-type="fig"}). COL3A1 was expressed in cytoplasm and nucleus and its expression in cancer epithelial and stromal region varied (Figure [1C-1F](#F1){ref-type="fig"}). To precisely measure the protein expression of COL3A1, we quantified the staining intensity and proportion using the positive pixel count algorithm in Aperio ImageScope software. The negative, weak positive, positive and strong positive pixels were colored as blue, yellow, orange and red, respectively (Figure [2G](#F2){ref-type="fig"}). In consistent with the mRNA expression, COL3A1 protein was significantly upregulated in cancer epithelial tissues comparing with the normal tissues (unpaired Student\'s *t* test, *p* = 3.4E-33, *n* = 84, or paired Student\'s *t* test, *p* = 4.6E-22, *n* = 76) (Figure [2H](#F2){ref-type="fig"}). However, no significant difference of COL3A1 expression was found between normal and CRC stromal regions (unpaired Student\'s *t* test, *p* = 0.316, *n* = 85, or paired Student\'s *t* test, *p* = 0.335, *n* = 79) (Figure [2I](#F2){ref-type="fig"}).

![IHC analysis of COL3A1 expression in CRC tissues\
Negative **A**. or positive **B.** expression of COL3A1 in colonic paraneoplastic mucosa tissues revealed by IHC analysis of a commercial TMA containing 90 cases. The region in the red box was enlarged and displayed to the right side. Scale bar = 400 μm. An area was further enlarged to show the stromal staining of COL3A1. **C.** Low expression of COL3A1 in colorectal adenocarcinoma epithelium. **D.** High expression of COL3A1 in colorectal adenocarcinoma epithelial cells. **E.** Low stromal expression of COL3A1 in the colorectal adenocarcinoma tissue selected from **C.** which was highlighted with blue box. **F.** High stromal expression of COL3A1 in the colorectal adenocarcinoma tissue enlarged from **D.** with blue box. **G.** Pseudo-colored markup of the CRC sample core in **D.** produced by the positive pixel count algorithm in image viewing software Aperio ImageScope v12. **H.** Statistics of epithelial expression of COL3A1 in the colorectal adenocarcinoma and colonic paraneoplastic mucosa tissues based on the positivity values calculated using the positive pixel count algorithm. The left scatterplot displayed the expression of COL3A1 in 82 normal tissues and 84 colorectal cancer (CRC) tissues. The epithelial cells were missing in some other tissues. The *p* values were calculated by unpaired two-sided Student\'s *t* test and *p* value \< 0.05 was considered as statistically significant. The right scatterplot showed only the 76 paired caner-normal tissues. The *p* value is calculated using paired Student\'s *t* test. **I.** Statistics of stromal expression of COL3A1 in unpaired (left) or paired (right) colorectal adenocarcinoma tissues and colonic paraneoplastic mucosa tissues.](oncotarget-07-8823-g002){#F2}

Associations of *COL3A1* mRNA and protein expressions with CRC clinicopathological characteristics {#s2_2}
--------------------------------------------------------------------------------------------------

We analyzed the relationship of *COL3A1* mRNA level with the clinicopathological characteristics of CRC patients using available Oncomine datasets. *COL3A1* expression was dichotomized into lower-than-median and higher-than-median groups. Expression of *COL3A1* was significantly associated with overall stage (Smith Colorectal \[[@R18]\], *p* = 0.015), T stage (Bittner Colon, *p* = 0.018) and Dukes stage (Bittner Colon, *p* = 0.022; Jorissen Colorectal 3 \[[@R19]\], *p* = 2E-5) (Table [1](#T1){ref-type="table"}). A strong correlation between *COL3A1* overexpression and recurrence (Smith Colorectal, *p* = 0.006; Jorissen Colorectal 3, *p* = 0.008) and survival (Smith Colorectal, *p* = 0) was also evident. The analyses of two datasets suggested that expression of *COL3A1* mRNA was associated with age (Vilar Colorectal 2 \[[@R20]\], *p* = 0.014; Jorissen Colorectal 3, borderline *p* = 0.050) (Table [1](#T1){ref-type="table"}). There was an evident difference of *COL3A1* expression between male and female patients (Lin Colon 2 \[[@R21]\], *p* = 0.004). High *COL3A1* expression was correlated with smoking status of CRC patients (Bittner Colon, *p* = 0.033).

###### Correlation between the mRNA expressions of COL3A1 and clinicopathological variables in patients with colorectal cancer revealed by data-mining of Oncomine gene array datasets

  Dataset[^a^](#tfn_001){ref-type="table-fn"}   Clinicopathological parameters   Total cases   *COL3A1*[^b^](#tfn_002){ref-type="table-fn"}   χ2   *p*              
  --------------------------------------------- -------------------------------- ------------- ---------------------------------------------- ---- ------- -------- -------
  Bittner Colon (373)                           T stage                          Tis-T1        52                                             35   17      10.073   0.018
  T2                                            103                              47            56                                                                   
  T3                                            85                               35            50                                                                   
  T4                                            88                               47            41                                                                   
  Dukes stage                                   A                                49            33                                             16   7.607   0.022    
  B                                             101                              49            52                                                                   
  C-D                                           88                               38            50                                                                   
  Smoke                                         Never smoker                     179           100                                            79   4.523   0.033    
  Smoker                                        194                              87            107                                                                  
  Smith Colorectal (177)                        Stage                            I             24                                             19   5       10.468   0.015
  II                                            57                               27            30                                                                   
  III                                           57                               23            34                                                                   
  IV                                            39                               20            19                                                                   
  Recurrence                                    No recurrence                    109           62                                             47   7.502   0.006    
  Recurrence                                    36                               11            25                                                                   
  Survival                                      Alive                            104           64                                             40   12.78   0        
  Dead                                          73                               25            48                                                                   
  Jorissen Colorectal 3 (154)                   Dukes stage                      A             24                                             4    20      22.850   0.000
  B                                             54                               24            30                                                                   
  C                                             43                               30            13                                                                   
  D                                             33                               19            14                                                                   
  Recurrence                                    No recurrence                    27            20                                             7    6.641   0.008    
  Recurrence                                    92                               40            52                                                                   
  Age                                           20-49 years                      16            12                                             4    9.491   0.050    
                                                50 - 59 years                    29            17                                             12                    
                                                60 - 69 years                    43            20                                             23                    
                                                70 - 79 years                    46            21                                             25                    
                                                80+ years                        24            7                                              17                    
  Lin Colon 2 (149)                             Sex                              Male          70                                             26   44      8.224    0.004
                                                Female                           79            49                                             30                    
  Vilar Colorectal 2 (104)                      Age                              40-59 years   22                                             16   6       10.650   0.014
                                                60 - 69 years                    42            26                                             16                    
                                                70 - 79 years                    73            29                                             44                    
                                                80+ years                        39            17                                             22                    

The analysis was performed using datasets from the Oncomine cancer gene expression microarray DB (<https://www.oncomine.org/resource/login.html>). The numbers in the blankets represent the total cases.

*COL3A1* mRNA expression was dichotomized into lower-than-median (\< M) and higher-than-median (≥ M) groups.

The overexpression of COL3A1 protein in CRC, based on the positivity by IHC and pixel analysis, was significantly associated with grade (χ2 = 6.731, *p* = 0.029), overall stage (χ2 = 8.438, *p* = 0.004) and T stage (χ2 = 6.923, *p* = 0.012) (Table [2](#T2){ref-type="table"}). However, stromal expression of COL3A1 had no significant relationship with any clinicopathological parameters ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

###### Correlation of COL3A1 protein expression in cancer epithelial cells with clinicopathological variables in CRC patients revealed by TMA-IHC analysis

  Clinicopathological factor       Total cases   COL3A1 protein[^a^](#tfn_003){ref-type="table-fn"}   χ2   *p* value   
  -------------------------------- ------------- ---------------------------------------------------- ---- ----------- -------
  Gender                                                                                                               
  Male                             43            25                                                   18   3.06        0.08
  Female                           41            16                                                   25               
  Age                                                                                                                  
  \< 65 years                      30            16                                                   14   0.392       0.531
  ≥ 65 years                       52            24                                                   28               
  Grade                                                                                                                
  I                                5             5                                                    0    6.731       0.029
  I-II, II                         45            18                                                   27               
  I-III, II-III, III               34            18                                                   16               
  Vascular Invasion Present                                                                                            
  Positive                         3             1                                                    2    0.307       1
  Negative                         34            17                                                   17               
  Number of Positive Lymph Nodes                                                                                       
  \< 1                             46            25                                                   21   1.141       0.285
  ≥ 1                              31            13                                                   18               
  T stage                                                                                                              
  T1-T2                            9             8                                                    1    6.923       0.012
  T3-T4                            73            31                                                   42               
  N stage                                                                                                              
  N0                               52            28                                                   24   1.386       0.239
  N1-N2                            32            13                                                   19               
  M stage                                                                                                              
  M0                               81            39                                                   42   0.003       1
  M1                               2             1                                                    1                
  Stage                                                                                                                
  1                                7             7                                                    0    8.438       0.004
  2-4                              75            32                                                   43               
  Metastasis                                                                                                           
  No                               82            40                                                   42   0.001       1
  Yes                              2             1                                                    1                
  Tumor volume (cm3)                                                                                                   
  \< 70                            55            25                                                   30   0.49        0.484
  ≥ 70                             28            15                                                   13               

The epithelial cell-specific expression of COL3A1 was dichotomized into low (L) or high (H) groups based on the positivity values calculated by the positive pixel count algorithm (v9.1) provided by the Aperio ImageScope v12.1.

Upregulated *COL3A1* mRNA predicts poor prognosis of CRC patients {#s2_3}
-----------------------------------------------------------------

Next, we proceeded to determine whether the overexpression of *COL3A1* mRNA associates with the prognosis of CRC patients or not. Smith Colorectal dataset in the Oncomine DB contains 177 cases, including 73 completed cases and 104 censored cases. Using Kaplan-Meier method, high expression of *COL3A1* mRNA was found to be significantly associated with poor prognosis of CRC patients in over-all survival (OS) analysis (log-rank test (LRT), *p* = 0.003) (Figure [3A](#F3){ref-type="fig"}). Since the above analysis indicated that *COL3A1* expression correlated with age and gender, we asked if the combination of these parameters associated with outcome. Either in female or male patients, high expression of *COL3A1* correlated with worse survival (LRT, *p* = 0.030) (Figure [3B](#F3){ref-type="fig"}). Although younger (age ≤ 65) or older (age \> 65) patients had no significant difference in survival when *COL3A1* was low (LRT, *p* = 0.099) (Figure [3C](#F3){ref-type="fig"}), the survival of older patients with high *COL3A1* was considerably worse than younger patients with high *COL3A1* (LRT, *p* = 0.010) (Figure [3D](#F3){ref-type="fig"}). An increased level of *COL3A1* mRNA also predicted worse recurrence-free outcome of CRC patients (LRT, *p* = 0.025) (Figure [3E](#F3){ref-type="fig"}). Different combinations of gender or age with *COL3A1* expression had no significant difference in their disease-free survival (DFS) (Figure [3F-3H](#F3){ref-type="fig"}).

![Kaplan-Meier analyses of *COL3A1* mRNA and protein expression in CRC patients\
**A.**-**F.** Survival analysis of *COL3A1* gene expression in CRC using Smith Colorectal dataset from Oncomine DB \[[@R18]\]. **A.** Overall survival (OS) analysis of low **L.** and high **H.** gene expression of *COL3A1* based on the median value of Log2 median-centered intensity (or ratio). The *p* value was calculated with Log-rank test (LRT) using GraphPad Prism 6. Case numbers were indicated in the brackets. **B.** OS analysis of female/low expression of COL3A1 (F-L), female/high expression (F-H), male/low expression (M-L) and male/high expression (M-H). **C.** OS analysis of young (age \> 65) or old (age ≤ 65) with lower-than-median expression of *COL3A1*. **D.** OS analysis of young (age \> 65) or old (age ≤ 65) with higher-than-median expression of *COL3A1*. **E.** Disease-free survival (DFS) analysis of *COL3A1* expression as in **A.**. **F.** DFS analysis of different combinations of gender and *COL3A1* expression. **F.** DFS analysis of different combinations of gender and *COL3A1* expression as in **B.**. **G.** DFS analysis of young (age \> 65) or old (age ≤ 65) with lower-than-median expression of *COL3A1*. **H.** DFS analysis of young (age \> 65) or old (age ≤ 65) with higher-than-median expression of *COL3A1*. **I.** OS analysis of the epithelial expression of COL3A1 protein using the Kaplan-Meier method by the IHC assay. High epithelial expression of COL3A1 was significantly associated with poor outcome of CRC patients. **J.** OS analysis of the stromal expression of COL3A1 protein using the Kaplan-Meier method by the IHC assay.](oncotarget-07-8823-g003){#F3}

Univariate and multivariate Cox regression analyses were performed to evaluate the association of *COL3A1* and clinic factors with prognostic hazards. In univariate Cox analysis, *COL3A1* (*p* = 0.004), grade (*p* = 0.004), recurrence status (*p* = 0.000) and stage (*p* = 0.000) were found to have an adverse impact on OS (Table [3](#T3){ref-type="table"}). Whereas increased *COL3A1* (*p* = 0.027), high grade (*p* = 0.003), recurrence status (*p* = 0.000) and high stage (*p* = 0.000) were significantly associated with inferior DFS (Table [3](#T3){ref-type="table"}). In multivariate analysis, both recurrence status and stage were significant predictors of OS (recurrence: Hazard ratio (HR) = 4.084, *p* = 0.000; stage: HR = 1.554, *p* = 0.033) and DFS (recurrence: HR = 8.276, *p* = 0.000; stage: HR = 1.536, *p* = 0.029) (Table [3](#T3){ref-type="table"}).

###### Univariate and multivariate Cox regression analyses of COL3A1 mRNA expression and clinical variables for overall and disease-free survival of CRC patients[^a^](#tfn_004){ref-type="table-fn"}

  Survival                Methods                       Variables    β[^b^](#tfn_005){ref-type="table-fn"}   SE (β)[^c^](#tfn_006){ref-type="table-fn"}   Wald χ2   *p*     Hazard ratio   95% CI[^d^](#tfn_007){ref-type="table-fn"}   
  ----------------------- ----------------------------- ------------ --------------------------------------- -------------------------------------------- --------- ------- -------------- -------------------------------------------- --------
  Overall-survival                                                                                                                                                                                                                      
                          Univariate Cox regression                                                                                                                                                                                     
                                                        Age          0.006                                   0.009                                        0.472     0.492   1.006          0.988                                        1.025
                                                        COL3A1       0.720                                   0.247                                        8.517     0.004   2.055          1.267                                        3.333
                                                        Grade        0.695                                   0.241                                        8.311     0.004   2.004          1.249                                        3.215
                                                        Recurrence   1.569                                   0.308                                        25.958    0.000   4.801          2.625                                        8.778
                                                        Sex          0.100                                   0.237                                        0.176     0.675   1.105          0.694                                        1.759
                                                        Stage        1.049                                   0.154                                        46.482    0.000   2.854          2.111                                        3.859
                          Multivariate Cox regression                                                                                                                                                                                   
                                                        Recurrence   1.407                                   0.315                                        20.010    0.000   4.084          2.205                                        7.565
                                                        Stage        0.441                                   0.207                                        4.531     0.033   1.554          1.036                                        2.333
  Disease-Free survival                                                                                                                                                                                                                 
                          Univariate Cox regression                                                                                                                                                                                     
                                                        Age          0.003                                   0.008                                        0.116     0.733   1.003          0.986                                        1.020
                                                        COL3A1       0.500                                   0.226                                        4.903     0.027   1.648          1.059                                        2.565
                                                        Grade        0.692                                   0.230                                        9.062     0.003   1.997          1.273                                        3.133
                                                        Recurrence   2.272                                   0.293                                        60.110    0.000   9.703          5.463                                        17.235
                                                        Sex          0.051                                   0.222                                        0.052     0.819   1.052          0.681                                        1.626
                                                        Stage        0.985                                   0.141                                        48.820    0.000   2.677          2.031                                        3.528
                          Multivariate Cox regression                                                                                                                                                                                   
                                                        Recurrence   2.113                                   0.299                                        49.839    0.000   8.276          4.603                                        14.882
                                                        Stage        0.429                                   0.197                                        4.742     0.029   1.536          1.044                                        2.259

The analysis was performed using the Smith Colorectal dataset from the Oncomine cancer gene expression microarray DB (<https://www.oncomine.org/resource/login.html>).

β, regression coefficient.

SE, standard error.

CI, confidence interval.

Epithelial but not stromal expression of COL3A1 protein associated with poor outcome of CRC {#s2_4}
-------------------------------------------------------------------------------------------

Different from gene expression microarray, protein IHC provides more information of the protein expression location and the abundance difference between locations. Interestingly, the increased COL3A1 protein in cancer epithelial region was significantly associated with poor OS revealed by the Kaplan-Meier analysis (LRT, *p* = 0.03) (Figure [3I](#F3){ref-type="fig"}). However, cancer stromal expression of COL3A1 had no significant relationship with OS (LRT, *p* = 0.669) (Figure [3J](#F3){ref-type="fig"}).

Univariate Cox regression analysis revealed that COL3A1 (epithelial) (*p* = 0.030), T stage (*p* = 0.002), N stage (*p* = 0.000), M stage (*p* = 0.000), stage (*p* = 0.000) and metastasis status (*p* = 0.002) were significantly associated with inferior OS (Table [4](#T4){ref-type="table"}). While multivariate analysis indicated that T (HR = 2.173, *p* = 0.001), N (HR = 1.233, *p* = 0.000) and M stage (HR = 37.056, *p* = 0.001) were independent hazard factors of CRC patients (Table [4](#T4){ref-type="table"}).

###### Univariate and multivariate Cox regression analyses of COL3A1 protein expression in cancer epithelial cells and clinical variables for overall survival of CRC patients

  Methods                       Variables             β[^a^](#tfn_008){ref-type="table-fn"}   SE (β)[^b^](#tfn_009){ref-type="table-fn"}   Wald χ2   *p*     Hazard ratio   95% CI[^c^](#tfn_010){ref-type="table-fn"}   
  ----------------------------- --------------------- --------------------------------------- -------------------------------------------- --------- ------- -------------- -------------------------------------------- ---------
  Univariate Cox regression                                                                                                                                                                                              
                                Age                   0.010                                   0.011                                        0.910     0.340   1.010          0.989                                        1.032
                                Gender                −0.323                                  0.289                                        1.245     0.264   0.724          0.411                                        1.276
                                COL3A1 (epithelial)   0.719                                   0.332                                        4.697     0.030   2.053          1.071                                        3.935
                                Grade                 0.223                                   0.150                                        2.228     0.136   1.250          0.932                                        1.677
                                T                     0.636                                   0.207                                        9.442     0.002   1.889          1.259                                        2.834
                                N                     0.428                                   0.098                                        19.094    0.000   1.534          1.266                                        1.859
                                M                     2.350                                   0.626                                        14.099    0.000   10.484         3.075                                        35.747
                                Stage                 0.271                                   0.068                                        15.794    0.000   1.311          1.147                                        1.499
                                Metastasis            2.315                                   0.757                                        9.341     0.002   10.123         2.294                                        44.664
                                COL3A1 (stromal)      0.128                                   0.302                                        0.181     0.671   1.137          0.629                                        2.055
                                Tumor volume          0.000                                   0.000                                        2.002     0.157   1.000          1.000                                        1.001
  Multivariate Cox regression                                                                                                                                                                                            
                                T                     0.776                                   0.244                                        10.124    0.001   2.173          1.347                                        3.506
                                N                     0.426                                   0.111                                        14.815    0.000   1.532          1.233                                        1.903
                                M                     3.612                                   1.038                                        12.101    0.001   37.056         4.841                                        283.663

β, regression coefficient.

SE, standard error.

CI, confidence interval.

COL3A1 is a plasma marker of CRC {#s2_5}
--------------------------------

To address the diagnostic significance of circulated COL3A1 as a protein marker of CRC, we analyzed the plasma concentration of COL3A1 using ELISA method. The sample information and ELISA results were deposited in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. Plasma COL3A1 of the CRC patients (*n* = 86), but not enteritis (*n* = 21) and polyps (*n* = 3) patients, was significantly higher than that of the healthy donors (*n* = 68) (unpaired Student\'s *t* test, *p* = 1.3E-10) (Figure [4A](#F4){ref-type="fig"}). The average concentration of plasma COL3A1 in the CRC group (134.05 ng/mL) was 5.4 fold higher than that in the healthy group (24.68 ng/mL). The average COL3A1 level (21.83 ng/mL) in the enteritis group was similar to the normal group, after excluding an extreme value. No matter what sex the patient was, plasma COL3A1 was significant higher in CRC than healthy donors (Figure [4B](#F4){ref-type="fig"}). While plasma COL3A1 had no difference between male and female in normal or CRC patients. In younger (age \< 60) or older (age ≥ 60) individuals, plasma COL3A1 was significantly higher in the cancer group than the healthy group (Figure [4C](#F4){ref-type="fig"}). Interestingly, plasma COL3A1 was notably increased in older peoples in either healthy (*p* = 0.016) or cancer individuals (*p* = 0.046). Receiver operating characteristic (ROC) curve analysis revealed that plasma COL3A1 had an area under curve (AUC) of 0.92, indicating a good prediction power for CRC (Figure [4D](#F4){ref-type="fig"}). The best diagnostic sensitivity and specificity of plasma COL3A1 were 98.8% and 69.1%, respectively, at a plasma concentration of 54.23 ng/mL. For comparison, we measured the plasma concentration of carcino-embryonic antigen (CEA), a typical tumor marker currently used for diagnosis. CEA was low in the normal (average = 1.49 ng/mL), enteritis (average = 0.95 ng/mL) and polyps group (average = 1.74 ng/mL), but was considerably increased by 17 fold in the CRC group (average = 17.08 ng/mL) (Figure [4E](#F4){ref-type="fig"}). The AUC of plasma CEA was 0.791, with the best diagnostic sensitivity and specificity of CEA were 70.2% and 73.0%, respectively, at a plasma concentration of 1.68 ng/mL (Figure [4F](#F4){ref-type="fig"}). The results demonstrated that plasma COL3A1 was comparable to CEA in CRC diagnosis.

![Elevated plasma COL3A1 protein is a potential diagnostic marker of CRC\
**A.** The plasma expressions of COL3A1 in 68 healthy individuals, 86 CRCs, 21 enteritis and 3 polyps patients were measured using a sandwich ELISA method. The concentration of COL3A1 was calculated comparing with the standard curve. The *p* values were calculated using two-sided Student\'s *t* test and a *p* value \< 0.05 was considered as statistically significant. The case numbers were indicated below each categories. **B.** Comparison of plasma COL3A1 between normal/male (N/M), normal/female (N/F), CRC/male (C/M) and CRC/female (C/F). ns, non-significant. **C.** Comparison of plasma COL3A1 between normal/(age \< 60), normal/(age ≥ 60), CRC/(age \< 60) and CRC/(age ≥ 60). **D.** ROC curve analysis of plasma COL3A1 in the CRC patients (*n* = 86) and the healthy controls (*n* = 68). The best diagnostic sensitivity and specificity of COL3A1 were 98.8% and 69.1%, respectively, at a plasma concentration of 54.23 ng/mL. AUC, area under curve. FPR, false positive rate. **E.** ELISA analysis of carcino-embryonic antigen (CEA) in the plasma samples. **F.** ROC analysis of CEA in the same set of plasma samples. The best diagnostic sensitivity and specificity of CEA were 70.2% and 73.0%, respectively, at a plasma concentration of 1.68 ng/mL. **G.** ROC analysis of the epithelial and stromal expression of COL3A1 in CRC tissues using IHC results. The best sensitivity and specificity of epithelial COL3A1 were 95.2% and 91.1%, respectively. The best sensitivity and specificity of stromal COL3A1 were 38.1% and 86.1%, respectively. **H.** ROC analysis of the mRNA expression of *COL3A1* in CRC tissues using Gaedcke Colorectal dataset in Oncomine database \[[@R22]\]. The best sensitivity and specificity were 76.9% and 92.3%, respectively. **I.** ROC analysis of the mRNA expression of *COL3A1* in CRC tissues using TCGA Colorectal dataset in Oncomine database. The best sensitivity and specificity were 82.8% and 81.8%, respectively.](oncotarget-07-8823-g004){#F4}

We also analyzed the predictive power of COL3A1 expression in TMA of CRC. The epithelial expression of COL3A1 had the best AUC of 0.975, and the best sensitivity and specificity were 95.2% and 91.1%, respectively (Figure [4G](#F4){ref-type="fig"}). However, the stromal expression of COL3A1 had no clinic prediction value with an AUC of 0.573 (Figure [4G](#F4){ref-type="fig"}). We further evaluated the capability of *COL3A1* mRNA expression to distinguish CRC patients from healthy people. ROC analysis using Gaedcke Colorectal dataset in Oncomine database \[[@R22]\] revealed that *COL3A1* gene expression had an AUC of 0.829 and the best sensitivity and specificity were 76.9% and 92.3%, respectively (Figure [4H](#F4){ref-type="fig"}). In TCGA Colorectal dataset, the AUC of COL3A1 was 0.863 by ROC analysis and the best sensitivity and specificity were 82.8% and 81.8%, respectively (Figure [4I](#F4){ref-type="fig"}).

COL3A1 promotes CRC cell proliferation by stimulating PI3K-AKT signaling {#s2_6}
------------------------------------------------------------------------

It was intriguing that COL3A1 protein localized on nucleus of cancer epithelial cells, in addition to the cytoplasm and extracellular space (Figure [2](#F2){ref-type="fig"}). This observation has never been documented in previous studies. It raised a hypothesis that COL3A1, a typical extracellular matrix (ECM) protein, might function as a signaling molecule within nucleus. We first analyzed the expression of COL3A1 in CRC cell lines. As shown in Figure [5A](#F5){ref-type="fig"}, COL3A1 was abundantly expressed in SW-620, SW-480 and HCT-116 cells. Endogenous *COL3A1* was stably silenced in SW-620 using short hairpin RNAs (shRNAs), and cell proliferation was measured using the methylthiazolyldiphenyl-tetrazolium bromide (MTT) method. The proliferation of SW-620 cells was suppressed by *COL3A1* knockdown (Figure [5B](#F5){ref-type="fig"}). We further analyzed *COL3A1* silencing *in vivo* using a zebra fish xenograft model, which has been used in cancer proliferation, cell invasion and metastasis analyses \[[@R23]\]. Endogenous *COL3A1* was silenced with a small interference RNA (siRNA) and the cells were treated with a fluorescent dye before inoculated into the fish yolk. The fluorescence in the yolk was measured to reflect the proliferation. As displayed in Figure [5C](#F5){ref-type="fig"}, *COL3A1* knockdown notably reduced cancer cell proliferation 2 days post-inoculation. Next we asked what signaling pathway(s) that *COL3A1* might stimulate. After *COL3A1* silencing, p-AKT^T308^, p-AKT^S473^ and p-mTOR^S2448^ were downregulated while p-GSK-3α/β^S21/9^ was upregulated, indicating a phosphorylation cascade of PI3K/AKT pathway (Figure [5D](#F5){ref-type="fig"}). Meanwhile, c-Myc was notably suppressed while p-ERK and cyclin D1 were less affected. These observation suggested loss of *COL3A1* inhibited PI3K/AKT and WNT signaling in CRC cells.

![Silencing of COL3A1 promotes CRC cells proliferation\
**A.** COL3A1 protein expression was measured in CRC cell lines. **B.** *COL3A1* was silenced in SW-620 cells with shRNAs and the growth of SW-620 was analyzed using MTT method. *p* value \< 0.05 was indicated with \*, while *p* \< 0.01 was indicated with \*\*. **C.** Zebra fish cancer xenograft assay of SW-620 cells with silenced *COL3A1* by a siRNA. The photos at the same time point were acquired with the same exposure time setting. The inserted pictures were modified photos with increased brightness to show the fishes. The arrowheads indicated the positions of amplified CRC cells. The silencing of *COL3A1* was verified by Western blot (bottom left). The integrated density of fluorescence of amplified cells were calculated with Image J (lower right). The numbers of fishes were shown within the column. **D.** Western blot analyses of several signaling molecules by *COL3A1*-knockdown in CRC cells.](oncotarget-07-8823-g005){#F5}

DISCUSSION {#s3}
==========

In this study, by analyzing Oncomine datasets, we found that *COL3A1* expression was significantly upregulated in colon cancers (total 654 cases) comparing with normal controls (178 samples). Furthermore, *COL3A1* was increased in all six subtype of colorectal cancers. These observation were in line with previous findings that *COL3A1* gene was upregulated in colon cancers \[[@R12]-[@R15]\]. We further revealed that *COL3A1* expression was significantly associated with clinic parameters of CRC in different cohorts, like age, sex, stage, T stage, Dukes stage, tobacco consumption, recurrence and survival status. Whereas upregulation of COL3A1 protein was found to be associated with grade, stage and T stage of CRC patient. These observation suggested that COL3A1 was a potential molecular marker of CRC.

A previous report indicates that *COL3A1* gene had a prognostic implication in brain tumor \[[@R24]\]. However, its prognostic significance in CRC remains undetermined. Here we revealed that upregulation of *COL3A1* mRNA was significantly associated with poor outcome of CRC patients in OS or DFS analyses using Oncomine datasets. Kaplan-Meier survival analysis revealed that increased COL3A1 protein in cancer epithelial cells predicted worse prognosis. These results suggested that *COL3A1* mRNA and protein could be prognosis indicators of CRC. Univariate but not multivariate Cox regression analyses demonstrated that *COL3A1* mRNA and epithelial-specific COL3A1 protein expression were significant hazard factors for CRC. While multivariate analyses revealed that stage and recurrence (mRNA datasets) or T, N and M stage (the protein analysis) were independent risk factors. These results suggested that *COL3A1* might not be an independent (or major) hazard factor for CRC patient survival.

As a soluble extracellular protein, COL3A1 was expected to be released into circulation system. Here we analyzed the plasma COL3A1 of CRC patients using the ELISA method. Comparing with the healthy peoples, the CRC patients have significant higher concentration of circulating COL3A1. Interestingly, plasma COL3A1 had a good prediction power with an AUC of 0.92, a best sensitivity of 98.8% at a specificity of 69.1%. Plasma CEA had a poor prediction power but a better specificity than plasma COL3A1. Tissue staining of epithelial-specific COL3A1 expression had a superior prediction value of AUC 0.975 and the highest sensitivity/specificity of 95.2%/91.1%, which was comparable to spondin-2, another molecular marker of colon cancer \[[@R25]\]. However, stromal COL3A1 had less power to discriminate CRC from healthy individuals (AUC = 0.572). *COL3A1* mRNA could also be used as a molecular diagnostic marker. However, *COL3A1* mRNA expression did not performed as good as the epithelial COL3A1. After all, mRNAs were extracted from tissues mixed with heterogeneous type of cells, while IHC analysis had the advantage to focus on cancer-specific cells. Thus, plasma COL3A1 represents a convenient molecular marker for quick and non-invasive diagnosis, whereas the IHC staining of epithelial COL3A1 could be useful for post-surgery outcome evaluation.

COL3A1 has found to be increased in the stroma of other type of cancers \[[@R26]\]. We also previously identified COL3A1 in the secretome of colon cancer-associated fibroblast (CAF) \[[@R27]\]. However, by IHC analysis of CRC tissues, COL3A1 was unexpectedly found to be expressed in the nuclei of epithelial cells. This observation indicated that COL3A1 might be function as a nuclear protein in addition to be a secreted extracellular matrix protein. We found that COL3A1 promotes CRC cell proliferation by stimulating PI3K-AKT signaling, suggesting COL3A1 could be a potential therapeutic target.

In summary, our study demonstrated that COL3A1 mRNA and protein were upregulated in CRC which were associated with clinicopathological factors and poor survival, and COL3A1 was also increased in plasma of CRC patient. COL3A1 could be a potential diagnostic biomarker of colon cancer.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and cell culture {#s4_1}
---------------------------

CRC cell lines LoVo, SW-480, SW-620, Caco-2 and HCT-116 were purchased from the Cell Bank of Shanghai Institutes for Biological Sciences, China. SW480 and SW-620 cells were cultured in DMEM supplemented with 10% FBS. Caco-2 cells were cultured in DMEM supplemented with 20% FBS. LoVo cells were cultured in RPMI 1640 supplied with 10% FBS. HCT-116 and HT-29 cells were cultivated with McCoy\'s 5A medium (Gibco Life Technologies, Shanghai, China)/10% FBS. All media were supplemented with 1% penicillin and 1% streptomycin (Hyclone Laboratories, China). Cells were maintained in a humidified incubator at 37°C and 5% CO~2~.

Data-mining of oncomine gene expression microarray datasets {#s4_2}
-----------------------------------------------------------

We analyzed the mRNA expression of *COL3A1* in GC using the Oncomine cancer gene expression microarray database (DB) (<https://www.oncomine.org/resource/login.html>). The data retrieve and analysis method has been previously described in detail \[[@R25]\]. The Smith Colorectal dataset contains 177 cases, including 73 completed cases and 104 censored cases \[[@R18]\]. Other datasets used in current study were Gaedcke Colorectal \[[@R22]\], Hong Colorectal \[[@R28]\], Skrzypczak Colorectal 2 \[[@R29]\] and Kaiser Colon dataset \[[@R30]\]. In each datasets, the *COL3A1* expression was dichotomized into lower-than-median and higher-than-median expression group based on the Log2 median-centered intensity of *COL3A1* mRNA.

Antibodies {#s4_3}
----------

Antibodies of COL3A1 (13548-1-AP), cyclin D1 (60186-1-Ig) and PI3K (20583-1-AP) were purchased from Proteintech (Wuhan, Hubei, China). GAPDH antibody (CW0100) was bought from CWBIO, Beijing, China. Other antibodies were purchased from Cell Signaling Technology (CST): PDK1 (\#3062), p-PDK1S241 (\#3061), p-AktS473 (D9E, \#4060), p-AktT308 (244F9, 4056), p-p70S6KT389 (108D2, \#9234), p70 S6 Kinase (49D7, \#2708), p-mTORS2448 (\#2971), mTOR (\#2972), p-GSK-3α/βS21/9 (D17D2, \#8566) and GSK-3α/β (D75D3,\#5676).

RNA interference (RNAi) {#s4_4}
-----------------------

RNAi was performed by transfection of CRC cells with a siRNA against COL3A1. The siRNA for *COL3A1* and a negative control (siNC) were purchased from Shanghai GenePharma Co., Ltd. The siRNA sequence used for COL3A1 was: GAGACUACCUAUUGUAGAUdTdT. Transfection was performed using Lipofectamine 2000 (Life Technologies - Invitrogen) with the aid of OPTI-MEM reduced serum media (Life Technologies - Invitrogen) according to the manufacturer\'s instructions and the methods as described previously \[[@R27], [@R31], [@R32]\].

shRNA lentivirus production {#s4_5}
---------------------------

The shRNA lentiviral plasmid (pLKO.1) was obtained from The RNAi Consortium. The core sequences of shRNAs against *COL3A1* were as following: sh1-COL3A1, CCGTTCTCTGCGATGACATAA; sh2-COL3A1, ACACCGATGAGATTATGACTT; sh3-COL3A1, AGCTACGGCAATCCTGAACTT. A shRNA against luciferase was used as a control: GTGCGCTGCTGGTGCCAAC. Lentivirus was produced using HEK293FT cells with the second-generation packaging system psPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene plasmid12259) as described previously \[[@R31], [@R32]\].

Cellular protein extraction, Western blot and growth curve assay {#s4_6}
----------------------------------------------------------------

Protein extraction and Western blot were performed as described previously \[[@R31]\]. The proliferation of CRC cells was measured using MTT (Sigma-Aldrich, Shanghai, China) method in 96-well plate. Each time point had at least five replicates. The MTT transformed crystals were dissolved in DMSO. The absorbance at 490 nm was measured using an Epoch microplate spectrophotometer (BioTek).

Zebrafish xenograft cancer model {#s4_7}
--------------------------------

The maintenance of Zebrafish and cancer cell inoculation were performed according to the methods established as described previously \[[@R32]\]. The difference was that the CRC cells were stained with 6 μM fluorescent CellTracker CM-Dil (Invitrogen) at 37°C for 4 min, followed by a further incubation at 4°C for 15 min. The fishes were incubated for two days and photographed using a LEICA M205 FA stereo fluorescence microscope with the same exposure time for both the control and knockdown group. The magnification was 140 ×. The integrated density of fluorescence was measured using Image J 1.45s.

IHC analysis {#s4_8}
------------

IHC was performed with COL3A1 antibody at a 1:800 dilution using a commercial TMA (catalog no. HCol-Ade180Sur-04, Shanghai Outdo Biotech, China) according to an established protocol of Outdo Biotech as previously described \[[@R25], [@R27], [@R32]\]. The TMA consists of 90 pairs of colorectal adenocarcinoma tissues and the matched normal mucosa counterparts, including 49 completed cases and 41 censored cases. The surgical time was from July 2006 to May 2007 and the follow-up information was available from Nov. 2006 to Aug. 2014. The survival time was from 3 to 85 months with a median of 56 months and 46 patients had died. The clinicopathological features of the GC patients were listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. After stained sequentially with COL3A1 antibody and a second antibody, the TMA was incubated with a substrate 3,3′-diaminobenzidine (DAB) for color developing and the nuclei were counterstained with hematoxylin. The TMA was then scanned using Scanscope XT (Aperio Technologies). The interesting regions in each sample core, such as cancer epithelial cells, cancer stromal region, epithelial cells or lamina propria region in paired normal mucosa tissues, were selected and labeled at different layers with the annotation function in Aperio ImageScope (v12.1) software. While the unwanted areas within the selected regions were excluded with the negative labeling tool. The staining intensity and percentage of selected sample regions were quantified with default settings using the positive pixel count algorithm (v9.1) provided by the Aperio ImageScope. The pixels were recognized as negative, weak positive, positive and strong positive pixels based on the default color and intensity thresholds. A color markup was generated by the analysis, which was used for checking and verification of each selection and coloration. The positivity was calculated as that the number of positive pixels was divided by the total number of all negative and positive pixels in the analyzed region. The expression was dichotomized into low and high by the median positivity value.

ELISA {#s4_9}
-----

Clinic plasma samples from health individuals and CRC patients were collected from the First Affiliated Hospital of Soochow University, Jiangsu, China, and the study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Soochow University. The sample information was listed in [Supplementary Table 3](#SD1){ref-type="supplementary-material"}. The plasma samples were stored in small aliquots at −80°C before use. ELISA was performed using a sandwich enzyme immunoassay method with a pre-coated 96-well strip plate from an ELISA kit for COL3A1 (Cloud-Clone Corp product, purchased from Wuhao, Inc., Shanghai, China) according to the manufacturer\'s instructions. The optimal dilution of the plasma samples was determined by serial dilution, which was comparing with the results of diluted standard provided by the ELISA kit. The plasma samples were diluted 20 folds with PBS (pH 7.2) before analyzing. The reaction was developed using the tetramethyl benzidine (TMB) substrate and the absorbance was measured using a microplate reader at a wave length of 450 nm. The concentrations of COL3A1 in each plasma sample were calculated using the standard curve.

Statistical analysis {#s4_10}
--------------------

The significance was calculated using two-tailed Student\'s *t* test and a *p* value \< 0.05 was considered as statistically significant. The correlation between *COL3A1* expression and the clinicopathological parameters were evaluated by χ2 test using PASW Statistics 18. Kaplan-Meier survival curves were calculated using the log-rank test with GraphPad Prism 6.01 and a *p* value \< 0.05 was considered as statistically significant. Univariate or multivariate survival analyses using Cox proportional hazard regression model were performed using PASW Statistics 18. The ROC curve analysis was performed using GraphPad Prism 6.0.1 and the optimal concentration of COL3A1 was determined at the maximal sensitivity and specificity.
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